LL-37 sits in the gap between approved medicine and controlled substance, and nearly every practical question about it lives in that gap. The molecule is the 37-amino-acid C-terminal fragment of human cathelicidin (hCAP-18), a naturally occurring host defense peptide rather than a designed compound, and that biological pedigree carries no regulatory weight at all. The consequence that reaches a reader is not the legal abstraction but the oversight vacuum underneath it: nobody independently verifies what is in the vial.
LL-37 holds no marketing approval from any national medicines regulator and is not a scheduled controlled substance in the United States, leaving it sold as research-use-only material that no agency reviews for identity, purity, or dose accuracy.
No approval exists in the United States, the European Union, the United Kingdom, Japan, Australia, Canada, or any other jurisdiction with a functioning medicines regulator, and that holds for every route and every indication explored so far. Approval is a regulator's finding, made after reviewing a complete dossier, that a specific product at a specific dose by a specific route, made by a specific manufacturing process, shows benefit outweighing risk in a defined patient population. LL-37 has never entered that review, so nothing about it has been accepted or rejected.
| Criteria | Marketing approval | Designation or cleared IND |
|---|---|---|
| What it establishes | Benefit outweighs risk for a defined use | Development may proceed |
| Basis | Complete dossier reviewed by the regulator | Procedural acceptance, not a safety review |
| Permission to market | Yes, for the approved labeling only | No |
| Constitutes a safety finding | Yes, for that product and dose | No |
No LL-37 product has been approved by the FDA, the EMA, or any comparable regulator for any route or indication, so no agency has ever set a legitimate human dose for it or collected pharmacovigilance reports of harm from it.
Almost everyone reads the phrase backwards. Research use only is not a classification a regulator hands out after reviewing anything; it is a sentence a vendor prints on its own product, describing a claimed intent and working as a liability shield pointed at the seller's exposure. Under US law intended use is inferred from the whole commercial picture, including the claims made, the dosing information supplied, the vial sizes offered, and whether the product ships alongside syringes and bacteriostatic water.
| Requirement | Research-grade material | Pharmaceutical-grade under GMP |
|---|---|---|
| Identity testing | Not required | Required, released by a quality unit |
| Sterility and endotoxin limits | None | Specified and tested per batch |
| Label-to-content accuracy | No obligation | Verified before release |
| Facility inspection | No regulator holds authority | Regulator may inspect and force a recall |
Research use only is a vendor's own disclaimer rather than a regulatory clearance, and it carries no minimum standard for identity, purity, sterility, endotoxin load, or agreement between the amount in the vial and the amount printed on the label.
The answer splits by verb, and the split is sharper than the question suggests. LL-37 is not contraband: it is not scheduled under the Controlled Substances Act, it is not an anabolic steroid, and it carries none of the possession offenses, quantity thresholds, or trafficking penalties that attach to scheduled drugs. It is also not lawful merchandise for human use, and the legal weather sits heaviest on whoever sells it and whoever administers it.
LL-37 is not a scheduled controlled substance in the United States, so simple possession carries no criminal drug exposure, but introducing it into interstate commerce for human use is a prohibited act under federal food and drug law, enforced mainly through warning letters, import alerts, and seizures aimed at sellers.
Compounding law in the United States does not let a pharmacy start from any powder it can buy, and that structural fact closes the route most people assume is open. Off-label prescribing does not rescue it either, because off-label use applies to an approved drug turned to an unapproved purpose, and LL-37 has no approval to be off of.
A bulk drug substance used in compounding generally must carry a USP or NF monograph, be a component of an FDA-approved drug, or appear on the FDA's list of substances eligible for compounding, and LL-37 satisfies none of those three conditions.
It does not, and the reason is statutory rather than colloquial. Being made of amino acids does not make a 37-residue peptide an amino acid in the legal sense, any more than a brick wall is clay: the category means individual amino acids, not sequences assembled into a defined biological molecule. Supplement framing keeps reappearing because the supplement aisle carries a permission structure in the public mind that the research chemical bench does not.
LL-37 falls outside the statutory definition of a dietary ingredient because a synthetic 37-residue peptide is not a vitamin, mineral, botanical, or amino acid, and the drug preclusion provision independently excludes any article with a public clinical investigation history from being marketed as a supplement.
None, and that single word deserves to land before the qualifications arrive, because this is where the legal abstraction turns into something a person can be harmed by. No agency inspects the facility, reviews the process, tests the batch, releases the lot, audits the label, or holds authority to recall the product, since none of that machinery attaches to a substance that is not sold as a medicine. The certificate of analysis is where the gap gets papered over, because a COA is a document supplied by the party with a financial interest in the sale.
No agency inspects the facility, tests the batch, audits the label, or holds recall authority over research-grade LL-37, and independent analyses of purchased research peptides have repeatedly found material that was underdosed, overdosed, degraded, or contaminated with heavy metals or endotoxin.
The World Anti-Doping Code's prohibited list opens with a catch-all category for non-approved substances, capturing any pharmacological substance not addressed elsewhere on the list and holding no current approval by any governmental regulatory health authority for human therapeutic use. That category is prohibited at all times, in and out of competition, and the trigger is the absence of approval rather than any evidence of performance benefit. A substance can be prohibited while being useless, because the rule refuses to let athletes serve as the testing population for compounds no regulator has cleared.
The World Anti-Doping Code prohibits non-approved substances at all times, both in and out of competition, and LL-37 falls into that category because it holds no current approval from any governmental regulatory health authority for human therapeutic use.
A human record exists, which is more than many research peptides can claim, but it is small, early, and aimed somewhere other than where most buyers are looking. Route is not a detail here: a peptide applied to a wound bed acts locally and stays largely confined, while the same molecule injected reaches immune cells, endothelium, and mast cells throughout the body, which is where LL-37's mast cell activation and concentration-dependent cytotoxicity to mammalian cells would need systematic study.
LL-37's human clinical record consists of early and mid-stage topical trials in hard-to-heal venous leg ulcers and early-phase intratumoral investigation in skin cancer, with no completed confirmatory trial and no dataset characterizing the safety of repeated systemic exposure.
The vocabulary changes at every border while the architecture stays remarkably consistent. European Union medicines law defines a medicinal product functionally, by presentation and by function, so a substance presented as treating or preventing disease, or administered to modify a physiological function, is a medicinal product regardless of what the packaging calls it, and placing one on the market without a marketing authorisation is unlawful. The point that gets misunderstood most often is that import legality is set by the destination country, never by the origin.
| Criteria | European Union | United Kingdom | Australia |
|---|---|---|---|
| Regulator | EMA and national agencies | MHRA | TGA |
| Status of LL-37 | Unauthorised medicinal product | Unauthorised medicinal product | Not entered on the national register |
| Legitimate access | Registered trial or named-patient use | Registered trial or named-patient use | Special Access Scheme, Authorised Prescriber, or trial notification |
LL-37 is treated as an unapproved medicinal product across the European Union, the United Kingdom, and Australia, with legitimate access confined to registered trials or named-patient and special-access pathways, and import legality determined by the recipient's own country rather than by the vendor's jurisdiction.
Nothing exotic. LL-37 is not stuck because the route is blocked; it is stuck because the route runs to hundreds of millions of dollars over roughly a decade, and a naturally occurring human sequence is hard to protect with composition-of-matter patents. The molecule is difficult on its own terms too, with rapid proteolysis, a short plasma half-life, no oral availability, lost antimicrobial activity at physiological salt and serum concentrations, and a narrow separation between the concentrations that kill bacteria and those that damage mammalian cell membranes.
Approval would require a sponsor to lock a single indication and route, clear an investigational new drug application, and complete first-in-human, mid-stage, and confirmatory trials before filing a new drug application, which for a 37-residue peptide sits below the forty-amino-acid statutory line that would otherwise make it a biologics license application.
Educational use only. This article describes what the published scientific and clinical literature reports about LL-37. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
